The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
about
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerASDCD: antifungal synergistic drug combination databasePan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cellsPotent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyNew insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicObatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Autophagy as a therapeutic target in cancer.Histone deacetylase inhibitors: emerging mechanisms of resistance.Rational Combinations of Targeted Agents in AMLAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesPhase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid CancerHistone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Autophagy modulation for cancer therapyMocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.Regulation of autophagy in hematological malignancies: role of reactive oxygen species.Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.Therapeutic targets in cancer cell metabolism and autophagy.Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy.Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cellsCell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cellsObatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes.The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells.Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
P2860
Q28538435-B488E47B-30E0-47A4-9BD8-F721295E52BCQ28539135-90FB0823-82CB-4B58-9168-B8CBB454B35FQ28542827-C87C03D0-E2CA-4C13-A0AA-7B723A2808BFQ30538418-5EAC427D-042C-4E84-8AC8-27471E42C481Q33983255-689226B3-7CAB-4D1F-BDB9-C5433B4B7A7BQ34004454-5F07F1A3-EF6E-4B2A-9BB6-45F156E2267AQ34224278-C7F9B575-8B1A-4C26-9CA7-9AD49601FD75Q34817365-C0AF268A-5694-433D-946C-9A6F41E4FAA1Q35007971-4D041B98-A969-4814-8D84-E7A54FF413ECQ35591562-E058164F-86E8-4058-8FD1-B213C3352585Q35592607-285DD9FA-C5F9-4A42-8FDA-F52788CE55C7Q35750491-A87FADDE-9C14-4126-A3DD-043C127FDEBDQ36696524-624F54A6-F976-44E7-92BF-D94809E0C0B7Q36934314-A911121F-E9B4-4CDD-B870-221801EE0281Q37738239-80909368-7494-4BD6-8BDC-E6C341179D70Q37813392-02495F75-FCAF-4667-B6DF-974B0B8E76E6Q37821337-ECF565D6-07EA-4B57-98AA-DEDB26A68565Q37832082-C7C02084-5B0B-4B49-8A83-20D59A1094B0Q37873498-2E5DD6B1-3BD1-4B4A-98BE-99A15B647ABCQ37900322-6E130503-C3AB-49CB-B0B8-902E8A618BABQ37983083-40DE23D3-280C-4A02-ABD2-A1C674B14765Q38025264-231F5283-BDE8-4EB9-A2B8-B8ECE2A37D2EQ38331755-54F3F98F-3450-4081-BDD3-B51CBD047A99Q38722639-B265B2BD-2C98-4745-AF12-511BE1863DC1Q38850608-07778ED4-5A3C-4520-A581-3E871D49DB1EQ39142897-057052D3-84F5-41C4-930B-6603CC19938BQ39413089-9B89D014-A0B8-4521-9681-5C6E23D2FD74Q41913197-9701CB14-60AE-4E81-8E2E-90124F6B610DQ54173194-5E7EF532-068F-4467-A5A6-8BB20890BBB1Q54472192-C748E453-6C20-492A-9573-21CEC3617A0DQ57174958-3547987C-61A7-4162-8B39-9AC284F7C92A
P2860
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The combination of a histone d ...... both apoptosis and autophagy.
@en
The combination of a histone d ...... both apoptosis and autophagy.
@nl
type
label
The combination of a histone d ...... both apoptosis and autophagy.
@en
The combination of a histone d ...... both apoptosis and autophagy.
@nl
prefLabel
The combination of a histone d ...... both apoptosis and autophagy.
@en
The combination of a histone d ...... both apoptosis and autophagy.
@nl
P2093
P2860
P50
P1476
The combination of a histone d ...... both apoptosis and autophagy.
@en
P2093
Francesco Paolo Tambaro
Jean Viallet
Ming Zhang
Weigang Tong
P2860
P304
P356
10.1158/1078-0432.CCR-10-0032
P407
P577
2010-06-10T00:00:00Z